Keyword: Shire

Merck halves Keytruda's price in China; Takeda eyes selling Shire's Xiidra and Natpara; another ex-GSK scientist pleads guilty to trade secret theft.

Takeda hasn't closed its Shire buyout, but it's already thinking about which products to offload to pay down debt, according to Bloomberg.

A Takeda founder descendant blasts the Shire deal, as the company moves its U.S. HQ closer to Shire; Sanofi revamps two global units.

Takeda plans to shutter its Chicago-area U.S. headquarters and open a site somewhere in Boston after closing its Shire deal.

A senior member of the founding Takeda family spoke out against the Shire deal for the first time, calling it a betrayal of company culture.

Bayer's new hemophilia drug Jivi will have to square off against a cadre of other next-gen drugs from Shire, Sanofi and potentially Roche.

A group of drugmakers large and small scored FDA nods in a busy week for the agency.

Shire got a brand-new approval that could help it dominate the hereditary angioedema market for years—and rack up blockbuster sales in the process.

As the first oral Fabry disease drug, Amicus' Galafold is priced at a discount to Sanofi's standard therapy Fabrazyme, an $824 million seller.

Shire could fill Takeda's gap of late-stage assets; GSK lays off 1,000 as a Bangladesh plant nears closure; Laekna gets two Novartis cancer drugs.